| Autor: |
Packer, Milton, Januzzi, James L, Ferreira, Joao Pedro, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Brueckmann, Martina, Jamal, Waheed, Cotton, Daniel, Iwata, Tomoko, Zannad, Faiez, EMPEROR-Reduced Trial Committees and Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| ISSN: |
1388-9842 |
| Popis: |
AIMS: Circulating troponin is an important measure of risk in patients with heart failure, but it has not been used to determine if disease severity influences the responses to drug treatments in randomized controlled trials. METHODS AND RESULTS: In the EMPEROR-Reduced trial, patients with class II-IV heart failure and a reduced ejection fraction were randomly assigned to placebo or empagliflozin 10 mg daily and followed for the occurrence of serious heart failure and renal events. High-sensitivity cardiac troponin T (hs-cTnT) was measured in 3636 patients (>97%) at baseline, and patients were divided into four groups based on the degree of troponin elevation. With increasing concentrations of hs-cTnT, patients were progressively more likely to have diabetes and atrial fibrillation, to have New York Heart Association class III-IV symptoms and been hospitalized for heart failure within the prior year, and to have elevated levels of natriuretic peptides and worse renal function (P-trend |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text